In addition, POPLAR trial and Checkmate 026 trial showed similar observation, where higher TMB was associated with improved efficacy in NSCLC patients treated with PD-1 or PD-L1 inhibitor in the first- and second-line setting.39, 40. The gene discussed is CD274; the disease is non-small cell lung carcinoma.